Core Insights - eXoZymes Inc. is a pioneer in AI-engineered enzymes that convert sustainable feedstock into nutraceuticals, medicines, and essential chemicals [1] - CEO Michael Heltzen will present at the 2025 ThinkEquity Conference on October 30, 2025, in New York City [1] - Heltzen highlighted that synthetic biology has not scaled commercially despite significant investment, indicating a gap between investment and tangible results [1] Company Overview - eXoZymes focuses on the development of AI-engineered enzymes [1] - The company aims to transform sustainable feedstock into various essential products [1] Industry Context - The synthetic biology sector has faced challenges in achieving commercial scalability [1] - There is a notable disparity between the amount of investment in synthetic biology and the outcomes produced [1]
CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference
Accessnewswire·2025-10-23 20:50